Prakash Vishnu

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Robert D. McBane, Waldemar E. Wysokiński, Jennifer Le‐Rademacher et al. · Journal of Thrombosis and Haemostasis · 2019 · 578 citations

Medicine, Pharmacology, Pharmacotherapy +14

Reversal of the Estrogen Receptor–Negative Phenotype in Breast Cancer and Restoration of Antiestrogen Response

Jill Bayliss, Amy Hilger, Prakash Vishnu et al. · Clinical Cancer Research · 2007 · 116 citations

Medicine, Cancer Biology, Oncology +14

Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma

Guoan Chen, Xiaoju Wang, Jianjun Yu et al. · Cancer Research · 2007 · 106 citations · Full text

Life Sciences, Immunology, Oncology +17

Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia

Vivek Kumar, Sikander Ailawadhi, Leyla Bojanini et al. · Blood Cancer Journal · 2019 · 73 citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

Safety and Efficacy of <i>nab</i> -Paclitaxel in the Treatment of Patients with Breast Cancer

Prakash Vishnu, Vivek Roy · Breast Cancer Basic and Clinical Research · 2011 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17